Benzyl Carbamate

Benzyl Carbamate

SCHEMBL119804

CCOCC.NC(=O)OCc1ccccc1

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.56
LMNA P02545 3/20 0.50
L3MBTL1 Q9Y468 3/20 0.50
TDP1 Q9NUW8 3/20 0.50
MAPK1 P28482 2/20 0.50
KMT2A Q03164 2/20 0.50
SLC6A2 P23975 1/20 0.50
SLC6A3 Q01959 1/20 0.50
CYP3A4 P08684 1/20 0.46
TSHR P16473 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HCAR2 Q8TDS4 1/20 0.46
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA9 Q16790 1/20 0.45
RAB9A P51151 2/20 0.44
NPC1 O15118 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzyl Carbamate SCHEMBL10864834 0.89 ALDH1A1 (0.60) ALDH1A1LMNAL3MBTL1TDP1MAPK1
Benzyl Carbamate SCHEMBL23754732 0.89 ALDH1A1 (0.49) ALDH1A1LMNAL3MBTL1TDP1MAPK1
Benzyl Carbamate SCHEMBL8592590 0.89 ALDH1A1 (0.64) ALDH1A1LMNAL3MBTL1TDP1MAPK1
Benzyl Carbamate SCHEMBL6992838 0.89 ALDH1A1 (0.64) ALDH1A1LMNAL3MBTL1TDP1MAPK1
Benzyl Carbamate SCHEMBL30227819 0.89 ALDH1A1 (0.63) ALDH1A1LMNAL3MBTL1TDP1MAPK1
Benzyl Carbamate SCHEMBL30227887 0.89 ALDH1A1 (0.63) ALDH1A1LMNAL3MBTL1TDP1MAPK1
Benzyl Carbamate SCHEMBL1697 0.89 ALDH1A1 (0.63) ALDH1A1LMNAL3MBTL1TDP1MAPK1
Benzyl Carbamate SCHEMBL10700633 0.89 ALDH1A1 (0.63) ALDH1A1LMNAL3MBTL1TDP1MAPK1
Benzyl Carbamate SCHEMBL28086051 0.87 ALDH1A1 (0.62) ALDH1A1LMNAL3MBTL1TDP1MAPK1
Benzyl Carbamate SCHEMBL7386720 0.87 TSHR (0.60) ALDH1A1LMNAL3MBTL1TDP1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220031852-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2022-02-03 US disclosed
US-20200360521-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2020-11-19 US disclosed
US-9919060-B2 Treatment or prophylaxis of proliferative conditions UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2018-03-20 US disclosed
US-20170368188-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2017-12-28 US disclosed
EP-2857018-A1 Treatment or prophylaxis of proliferative conditions University Court of The University of Dundee (GB) 2015-04-08 EP disclosed
US-20150011512-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2015-01-08 US disclosed
US-20120302748-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS THE UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2012-11-29 US disclosed
US-8283340-B2 Treatment or prophylaxis of proliferative conditions The University of the University of Dundee (GB) 2012-10-09 US disclosed
US-20120190639-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2012-07-26 US disclosed
EP-2424524-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS University Court of The University of Dundee (GB) 2012-03-07 EP disclosed
EP-1233970-A2 PROTECTING GROUPS USEFUL IN THE SYNTHESIS OF POLYSACCHARIDES, NATURAL PRODUCTS, AND COMBINATORIAL LIBRARIES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2002-08-28 EP disclosed
US-6426421-B1 HALOGENATED BENZYL ETHER-BASED PROTECTING GROUPS FOR FUNCTIONAL GROUPS, OF ALCOHOLS, THIOLS, AMINES, CARBOXYLIC ACIDS, AND PHOSPHORIC ACIDS MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2002-07-30 US disclosed
US-6268338-B1 USEFUL AS AN ANTIBIOTIC, ESPECIALLY AS AN ANTIFUNGAL AGENT OR AS AN ANTIPROTOZOAL AGENT. MERCK & CO., INC. 2001-07-31 US disclosed
WO-2001038337-A2 PROTECTING GROUPS USEFUL IN THE SYNTHESIS OF POLYSACCHARIDES, NATURAL PRODUCTS, AND COMBINATORIAL LIBRARIES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2001-05-31 WO disclosed
US-5914313-A ANTIBIOTICS MERCK & CO., INC. (US) 1999-06-22 US disclosed
EP-0707488-A4 CYCLOHEXAPEPTIDYL AMINE COMPOUNDS MERCK & CO INC (US) 1998-01-14 EP disclosed
EP-0707488-A1 CYCLOHEXAPEPTIDYL AMINE COMPOUNDS MERCK & CO. INC. (US) 1996-04-24 EP disclosed
WO-1994025048-A1 CYCLOHEXAPEPTIDYL AMINE COMPOUNDS MERCK & CO., INC. (US) 1994-11-10 WO disclosed
WO-1994009033-A1 AN IMPROVED PROCESS FOR CYCLOHEXAPEPTIDYL BISAMINE COMPOUNDS MERCK & CO., INC. (US) 1994-04-28 WO disclosed
US-4820718-A PLATELET ACTIVATING FACTOR INHIBITORS SANDOZ PHARM. CORP. (US) 1989-04-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200360521-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS CYP1B1, UGT1A1, CYP1A1 ALDH1A1 55/4885LMNA 3222/4885L3MBTL1 3106/4885
US-20120302748-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS BRCA1, CYP1B1, UGT1A1 ALDH1A1 35/4885LMNA 2660/4885L3MBTL1 2848/4885
US-20120190639-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS CYP1B1, UGT1A1, CYP1A1 ALDH1A1 55/4885LMNA 3222/4885L3MBTL1 3106/4885
US-20220031852-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS CYP1B1, UGT1A1, CYP1A1 ALDH1A1 55/4885LMNA 3222/4885L3MBTL1 3106/4885
US-20170368188-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS CYP1B1, UGT1A1, CYP1A1 ALDH1A1 61/4885LMNA 2838/4885L3MBTL1 3445/4885
US-20150011512-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS CYP1B1, UGT1A1, CYP1A1 ALDH1A1 55/4885LMNA 3222/4885L3MBTL1 3106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.